CRNX Stock Overview
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Crinetics Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.01 |
| 52 Week High | US$49.58 |
| 52 Week Low | US$15.76 |
| Beta | 0.62 |
| 1 Month Change | -4.80% |
| 3 Month Change | 21.15% |
| 1 Year Change | 149.77% |
| 3 Year Change | 148.61% |
| 5 Year Change | 71.35% |
| Change since IPO | 75.48% |
Recent News & Updates
Recent updates
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
Apr 24Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Jan 19Crinetics Pharmaceuticals appoints Garlan Adams as general counsel
Jun 16Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
May 13Crinetics Pharmaceuticals EPS misses by $0.04
May 06Have Insiders Been Selling Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
Mar 21Companies Like Crinetics Pharmaceuticals (NASDAQ:CRNX) Are In A Position To Invest In Growth
Jan 27
Insider Buying: The Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Founder Just Bought US$65k Worth Of Shares
Dec 06Shareholder Returns
| CRNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.5% | -4.7% | -3.7% |
| 1Y | 149.8% | -2.7% | 20.2% |
Return vs Industry: CRNX exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: CRNX exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| CRNX volatility | |
|---|---|
| CRNX Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRNX has not had significant price volatility in the past 3 months.
Volatility Over Time: CRNX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 290 | R. Struthers | www.crinetics.com |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
Crinetics Pharmaceuticals, Inc. Fundamentals Summary
| CRNX fundamental statistics | |
|---|---|
| Market cap | US$3.35b |
| Earnings (TTM) | -US$214.53m |
| Revenue (TTM) | US$4.01m |
835.2x
P/S Ratio-15.6x
P/E RatioIs CRNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNX income statement (TTM) | |
|---|---|
| Revenue | US$4.01m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.01m |
| Other Expenses | US$218.54m |
| Earnings | -US$214.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.75 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,345.85% |
| Debt/Equity Ratio | 0% |
How did CRNX perform over the long term?
See historical performance and comparison